metoclopramide has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Excerpt | Relevance | Reference |
---|---|---|
"Metoclopramide is a good and cost-effective therapeutic option for chemotherapy-induced nausea and vomiting." | 1.62 | The anti-cancer effect of metoclopramide on triple-negative breast cancer cells. ( Chen, Y; Fan, R; Ji, X; Ji, Y; Liu, Y; Lu, P; Qin, S; Zhang, M; Zhao, J, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Chen, Y | 1 |
Zhang, M | 1 |
Ji, X | 1 |
Zhao, J | 1 |
Qin, S | 1 |
Ji, Y | 1 |
Fan, R | 1 |
Liu, Y | 1 |
Lu, P | 1 |
1 other study available for metoclopramide and ER-Negative PR-Negative HER2-Negative Breast Cancer
Article | Year |
---|---|
The anti-cancer effect of metoclopramide on triple-negative breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dopamine D2 Receptor Antagon | 2021 |